MINERVA SURGICAL ANNOUNCES $30 MILLION PRIVATE PLACEMENT OF COMMON STOCK LED BY ACCELMED PARTNERS

Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT). The companies will collaborate to develop and commercialize a novel mobile application, which combines multiple clinically validated therapeutic interventions for use alone and in combination with pharmaceutical therapy to help people with schizophrenia achieve positive clinical outcomes.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for CT-132. Click’s CT-132 prescription digital therapeutic is under development as an adjunctive preventive treatment for episodic migraine in patients aged 18 years and older.

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the MedTech industry, announced today that it has acquired Fusion Biotec (Fusion), a design and engineering leader for complex electro-mechanical diagnostic instrumentation and medical devices located in Orange, California.

— Darin Hammers appointed Chief Executive Officer —
— EGS closes on $18M financing to further drive growth and adoption of the Transoral Incisionless Fundoplication (TIF) procedure —

Helps Customized Rx Dermatology and Digital Health Company Accelerate Expansion of Product Offerings, Platform Technologies, and Operational Footprint to Enhance Practice Care

Veranex brings together best-in-class expertise in product design and engineering, medical device evaluation, clinical development, data management, regulatory, and market access to deliver an integrated and comprehensive solution to the MedTech market, enabling its customers to efficiently move from concept to commercialization.

The only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced today that it has acquired Medidee, a top MedTech consultancy company headquartered in Lausanne, Switzerland.

MedMinder, the leader in connected pharmacy care for polypharmacy and senior patients, announced today it has closed an additional $35 million in funding through a credit facility with SWK Holdings Corporation and additional investment from existing equity partner, Accelmed Partners.

While focusing on securing liquidity for our portfolio companies and taking measures to contain costs, we continue to seek new investments and are glad to report a new member of the Accelmed portfolio, Veranex.

Veranex — the only global, tech-enabled product development services provider focused on the medical technology industry — today announced strategic partnerships with Accelmed Partners II and Lauxera Capital Partners.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has closed a $52 million upsized Series B financing

Accelmed Partners I portfolio company Keystone Dental Inc. announced the acquisition of Osteon Medical and the completion of a $25 million financing round led by Nantahala, with participation from Accelmed and Migdal Insurance.

Accelmed Ventures portfolio company CartiHeal is being acquired by Bioventus for $350 million in upfront consideration and up to $500 million including earn-outs.

Memic, a portfolio company of Accelmed, signed a definitive agreement for a SPAC merger with MedTech Acquisition Corporation (Nasdaq: MTAC) with an equity value at over $1 billion.

CartiHeal released a study validating the clear clinical benefits of its Agili-C™ implant for the treatment of cartilage lesions in arthritic and non-arthritic joints. Accelmed was the first investor in CartiHeal.

Managing Partner Dr. Uri Geiger spoke with Duane Mancini, M. Sc. for the Project Medtech podcast and discussed his background, Israel’s medical device space and what they look for in a company, among other things.

Managing Partner Dr. Uri Geiger sat down for a Q&A with Sarah Pringle of PE Hub to discuss how Accelmed distinguishes itself from traditional private equity funds, its unique differentiators and more.

Accelmed bolsters its leadership team with the addition of two industry veterans, Eric Tansky and Stephen Rubin as General Partner and Partner respectively, as well as adding Lewis Pell and Stanley Stern to its Executives Network.

Managing Partner Dr. Uri Geiger sat down with Lauren R. Rublin and Nathan-Kazis for a discussion on developments in pharma and biotech investing, innovations in healthtech, or the intersection of healthcare and technology, private equity investing in the healthcare arena, and healthtech innovations in Israel.

Accelmed Partners Leads a $40 Million Investment in MedMinder, the leading fully-integrated, end-to-end pharmacy, medication adherence and connected care solution for elderly and polypharmacy patients.

Accelmed successfully closed its oversubscribed second fund at the Fund’s hard cap of $400 million, exceeding its original $300 million target.

Accelmed Fund II, unveiled in late 2019, wrapped up this month at its hard cap, 33 percent above an original target of $300 million, founder and managing partner Uri Geiger told Buyouts. Fund II is more than 3x the size of its predecessor, closed in 2016 at $130 million.